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During our continued search for bioactive metabolites from pathogenic microorganisms, we isolated and reported a novel tricyclic diterpenoid antibiotic, brasilicardin A ( Fig.   1 ), from a strain ofNocardia brasiliensisx;l\
In addition to the potent immunosuppressive activity of brasilicardin A in a mouse mixed lymphocyte reaction (MLR) assay system1'2), our recent studies indicated that the antibiotic shows an interesting antitumor spectrum. In this paper, we report its in vitro and in vivo antitumor activity.
Brasilicardin A was prepared from a culture broth of N. brasiliensis IFM 0406 as described previously1}. IC50 values against various cell lines were determined and compared with those of adriamycin. P388/ADR, P388, L1210 (mouse The IC50 values for brasilicardin A varied depending on the cell lines tested, ranging from 0.078 to 100 /ug/ml ( Table   1 ). P388 and P388/ADR cell lines were highly susceptible to brasilicardin A, with IC50 values of 0.22 and 0.078 jUg/ml, respectively.
Interestingly, the P388/ADR cell line was the most susceptible cell line to the antibiotic, followed by the parent P388 cell line. HeLa, MOLT-4 and CCRF-CEMcell lines belonged to less susceptible groups. Furthermore brasilicardin A was found to be less toxic at effective doses such as lOmg/kg because no body weight decrease was observed (Table 2) . It has been reported that the multidrug resistant JAN. 2000 mechanismof P388/ADR is due to the expression of Pglycoprotein, which acts by pumping antitumor agents out of cells4). Many immunosuppressive agents are known to reverse the multidrug resistance by inhibiting the activity of P-glycoprotein5'6).
Since our previous studies showed that brasilicardin A has immunosuppressive activity, we are interested in the effect of brasilicardin Aon P-glycoprotein, which was evaluated by monitoring its effect on the IC50 values of adriamycin against P388/APR. Verapamil and cyclosporin A (CyA) were used as positive controls of Pglycoprotein inhibition. P388/ADR cells were cultured with various concentrations of adriamycin in the presence of brasilicardin A, verapamil or CyA for 72 hours followed by MTT assay, and their effects on the susceptibility to adriamycin were observed. The IC50 of adriamycin was 1.0 jUg/ml in the absence of these test compounds (Table 3) . However, in the presence of verapamil at concentrations of 1 and 10fig/ml, the IC50 values of adriamycin decreased to 0.23 and 0.084^g/ml, respectively. CyA was also found to ongoing studies using various tumor cells with different resistance genes may help us understand the selective activity of brasilicardin A against P388/ADR cells. Our recent preliminary study indicated that brasilicardin A induces Gj-phase arrest of P388 cells in vitro. Therefore, it is reasonable to consider that brasilicardin A has different mechanisms of immunosuppressive activity from those of reference drugs such as CyA, although further detailed studies are necessary to understand the association between Gj-arrest activity of brasilicardin A and the unique narrow cytotoxic spectrum of the antibiotic.
